Heart failure - New insights

Israel Medical Association Journal

Volumn 11, Issue 2, 2009, Pages 105-111

  Blum, A ^a  

^a Poriya Hospital   (Israel)

Author keywords

Endothelial dysfunction; Heart failure; Reactive oxygen species

Indexed keywords

ENDOTHELIN; INTERLEUKIN 6;

APOPTOSIS; HEART FAILURE; HUMAN; INFLAMMATION; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

APOPTOSIS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 66149086498     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Blum A, Miller H. Role of cytokines in heart failure. Am Heart J 1998; 135: 181-186.
2. Cohn JN, Johnson G. Heart failure with normal ejection fraction: the V-HeFT Study. Circulation 1990; 81(Suppl III): III-48-III-53.
3. Garty M, Shotan A, Gottlieb S, et al. Te management, early and one-year outcome of hospitalized patients with heart failure: a national heart failure survey in Israel - HFSIS2003. IMAJ 2007; 9: 227-233.
4. Maack C, Kartes T, Kitler H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-1574.
5. Kjekshus J, Apertei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
6. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999; 100: 292-298.
7. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26: 65-69.
8. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001; 6: 71-80.
9. von Haehling S, Jankowska EA, Anker SD. Tumor necrosis factor alpha and the failing heart - pathophysiology and therapeutic implications. Basic Res Cardiol 2004; 99: 8-28.
10. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent onset dilated cardiomyopathy. Circulation 2001; 103: 2254-2259.
11. Gullestad L, Aass H, Fjeld JL, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
12. Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-391.
13. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin 6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21: 1787-1803.
14. Hilfker-Kleiner D, Hilfker A, Fuchs M, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004; 95: 187-195.
15. Brancaccio M, Fratta L, Notte A, et al. Melusin, a muscle specific integrin beta1 interacting protein is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 2003; 9: 68-75.
16. DeAccetis M, Notte A, Accornero F, et al. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ Res 2005; 96: 1087-1094.
17. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115: 565-571.
18. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-1504.
19. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141.
20. Ashrafan H, Frenneaux M P. Metabolic modulation in heart failure: the coming of age. Cardiovasc Drugs Ter 2007; 21: 5-7.
21. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991; 122: 795-801.
22. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-2196.
23. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-508.
24. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 1971; 50: 1386-1389.
25. Nissen SE, Wolski K. Efect of rosiglkitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
26. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007; 12: 331-343.
27. Nightingale AK, Crilley JG, Pegge NC, et al. Chronic oral ascorbic acid therapy worsens skeletal metabolism in patients with chronic heart failure. Eur J Heart Fail 2007; 9: 287-291.
28. Ventura-Clapier R, Mettauer B, Bigard X. Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure. Cardiovasc Res 2007; 73: 10-18.
29. Nakamura S, Naruse M, Naruse K, Demura H, Uemura H. Immunocytochemical localization of endothelin in cultured bovine endothelial cells. Histochemistry 1990; 94: 475-477.
30. Lee M-E, Bloch KD, Cliford JA, Quertermous T. Functional analysis of the endothelin 1 gene promoter: evidence for an endothelial cell-specifc cis-acting sequence. J Biol Chem 1990; 265: 10450-10466.
31. Ono K, Tsujimoto G, Sakamoto A, et al. Endotheline A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994; 370: 301-304.
32. Prins BA, Hu R-M, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-11944.
33. Lerman A, Hildebrand FL Jr, Aarhus LL, Burnett JC. Endothelin has biological actions at pathophysiological concentrations. Circulation 1991; 83: 1808-1814.
34. Katz SD, Krum H, Khan T, Knecht M. Exercise induced vasodilatation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium derived nitric oxide. J Am Coll Cardiol 1996; 28: 585-590.
35. Hare JM, Nguyen GC, Massaro AF, et al. Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure. J Am Coll Cardiol 2002; 40: 1114-1119.
36. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi-center randomization study. Cardiology 2008; 109: 273-280.
37. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33: 1424-1426.
38. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.
39. Nonaka-Sarukawa M, Yamamoto K, Aoki H, et al. Circulating endothelial progenitor cells in congestive heart failure. Int J Cardiol 2007; 119: 344-348.